Taiwan Liposome Company, Ltd. American Depository Shares
TLC
TLC was delisted on the 28th of September, 2021.
5 hedge funds and large institutions have $2.46M invested in Taiwan Liposome Company, Ltd. American Depository Shares in 2020 Q1 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 0 reducing their positions, and 1 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
17% less funds holding
Funds holding: 6 → 5 (-1)
31% less capital invested
Capital invested by funds: $3.57M → $2.46M (-$1.12M)
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$4K |
TLC Hedge Fund Activity: Q1 2020 in Review
5 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Taiwan Liposome Company, Ltd. American Depository Shares (TLC) for Q1 2020, worth a combined $2.46M — down 31% from $3.57M a quarter earlier.
Fund positioning in TLC was balanced in Q1 2020: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 0 trimmed.
The largest seller was UBS Group, exiting entirely with an estimated $4K sold.
- 5 institutional investors held Taiwan Liposome Company, Ltd. American Depository Shares (TLC) as of Q1 2020, down from 6 in Q4 2019.
- Funds reported $2.46M of Taiwan Liposome Company, Ltd. American Depository Shares stock for Q1 2020, down 31% quarter-over-quarter.
- 1 fund opened new Taiwan Liposome Company, Ltd. American Depository Shares positions in Q1 2020 and 1 closed out, a net change of 0 holders.
- The largest Taiwan Liposome Company, Ltd. American Depository Shares seller in Q1 2020 was UBS Group, an estimated $4K sold.
Based on aggregated 13F filings for Q1 2020.